Targeting a key protein to fight leukemia
Targeted Inhibition in Leukemia
This study is testing a new treatment that targets a specific protein in certain types of leukemia, aiming to help patients with Philadelphia-positive B-cell acute lymphoblastic leukemia and acute myeloid leukemia by making existing therapies work better and reducing side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10652352 on NIH RePORTER |
What this research studies
This research investigates a new small molecule inhibitor that targets Vav3, a protein involved in many cancers, including leukemia. The approach aims to eliminate resistance to existing therapies and improve survival rates in patients with Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) and acute myeloid leukemia (AML). By focusing on the specific cancer cells while sparing normal cells, the research seeks to minimize toxicity and enhance treatment efficacy. The study will also explore the inhibitor's effectiveness in various cancer models, particularly those resistant to current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Philadelphia-positive B-cell acute lymphoblastic leukemia or acute myeloid leukemia, especially those who have shown resistance to current treatments.
Not a fit: Patients with other types of leukemia or cancers not related to the Vav3 protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for leukemia, particularly for patients who have not responded to existing therapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Cincinnati, United States
- Cincinnati Childrens Hosp Med Ctr — Cincinnati, United States (Active)
Researchers
- Principal investigator: Nassar, Nicolas — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Nassar, Nicolas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.